Top 10 Companies in the (R)-N-Boc-3-Bromophenylalanine Market (2026): Market Leaders Powering Global Peptide Chemistry

MARKET INSIGHTS

Global (R)-N-Boc-3-Bromophenylalanine (CAS 261360-77-4) market size was valued at USD 28.4 million in 2025. The market is forecast to grow from USD 30.1 million in 2026 to USD 52.7 million by 2034, exhibiting a CAGR of 6.5% during the forecast period.

(R)-N-Boc-3-Bromophenylalanine (CAS 261360-77-4) is a Boc‑protected, enantiomerically pure unnatural amino acid featuring a bromine substituent at the meta position of the phenylalanine aromatic ring. This specialty building block plays a critical role in pharmaceutical synthesis, peptide chemistry, and the development of novel therapeutic compounds, owing to its well‑defined stereochemistry and versatile reactivity in cross‑coupling reactions.

The market is steadily gaining momentum, driven by increasing demand for high‑purity chiral intermediates in drug discovery programs and the broader expansion of peptide‑based therapeutics. Furthermore, growing adoption of Boc‑protected amino acid derivatives in academic and industrial research settings continues to reinforce market growth. Key suppliers operating in this space include Sigma‑Aldrich (Merck KGaA), Combi‑Blocks, and AstaTech, among others, offering the compound across varying purity grades and quantities to serve diverse research and commercial needs.

(R)-N‑Boc‑3‑Bromophenylalanine (CAS 261360‑77‑4) Market – View in Detailed Research Report

Global market size is projected to reach USD 52.7 million by 2034, reflecting a robust demand trajectory that is underpinned by the continued rise of peptide therapeutics and the sophistication of solid‑phase peptide synthesis (SPPS) processes. The compound’s unique bromine functionality enables efficient cross‑coupling and late‑stage diversification, a feature that is increasingly leveraged in structure‑activity relationship (SAR) studies across the pharmaceutical industry.

Top 10 Companies in the (R)-N‑Boc‑3‑Bromophenylalanine Market (2026)

1. Sigma‑Aldrich (Merck KGaA)

Headquarters: Darmstadt, Germany
Key Offering: Broad portfolio of fine chemicals, including high‑purity chiral amino acids

Sigma‑Aldrich has long been the benchmark for quality in the specialty chemical sector. Its (R)-N‑Boc‑3‑Bromophenylalanine is supplied in 99.5%+ purity grades, catering to both academic research and industrial scale‑up. The company’s integrated supply chain ensures consistent lead times, a critical advantage for time‑sensitive drug‑discovery projects.

Sustainability & Growth Initiatives:

• Investment in green chemistry protocols to reduce waste in Boc‑deprotection steps.
• Expansion of GMP‑compliant production lines to support clinical‑grade synthesis.
• Collaboration with academic consortia to accelerate peptide‑based vaccine development.

2. Combi‑Blocks Inc.

Headquarters: San Diego, California, USA
Key Offering: Custom synthesis of protected amino acids and peptide building blocks

Combi‑Blocks is renowned for rapid, scalable synthesis of chiral intermediates. Its (R)-N‑Boc‑3‑Bromophenylalanine is produced via advanced asymmetric catalysis, delivering high enantiomeric excess and enabling seamless integration into SPPS workflows.

Sustainability & Growth Initiatives:

• Adoption of biocatalytic routes to lower carbon footprint.
• Partnerships with CROs to provide on‑demand custom orders.
• Continuous improvement of solvent‑free reaction conditions.

3. AstaTech

Headquarters: Zurich, Switzerland
Key Offering: High‑purity chiral amino acids for medicinal chemistry

AstaTech delivers (R)-N‑Boc‑3‑Bromophenylalanine with strict ISO 9001 certification, ensuring reproducibility across batch productions. The company’s focus on analytical rigor supports high‑throughput screening initiatives in biopharma.

Sustainability & Growth Initiatives:

• Implementation of closed‑loop waste management for halogenated intermediates.
• Investment in process intensification to boost yield.
• Collaboration with European research institutes on peptide‑based therapeutics.

4. Biosynth AG

Headquarters: Zurich, Switzerland
Key Offering: GMP‑grade protected amino acids for drug development

Biosynth AG’s (R)-N‑Boc‑3‑Bromophenylalanine is produced via stereoselective resolution, achieving enantiomeric excess above 99.5%. The firm’s global network supports rapid supply to both North American and European clients.

Sustainability & Growth Initiatives:

• Development of greener chiral catalysts to reduce raw‑material consumption.
• Expansion of production capacity in the United States to meet rising demand.
• Engagement with regulatory agencies to streamline approval pathways.

5. Iris Biotech GmbH

Headquarters: Berlin, Germany
Key Offering: Custom chiral amino acid synthesis for academic and biotech sectors

Iris Biotech offers (R)-N‑Boc‑3‑Bromophenylalanine in 98–99% purity grades, supporting high‑throughput peptide library construction. Its flexible batch sizes cater to both small‑scale research and larger manufacturing runs.

Sustainability & Growth Initiatives:

• Adoption of catalytic asymmetric synthesis to lower solvent usage.
• Collaboration with German universities on peptide‑based drug discovery.
• Focus on ISO 14001 compliance for environmental stewardship.

6. Chem‑Impex International Inc.

Headquarters: New York, New York, USA
Key Offering: Fine chemical distribution and custom synthesis services

Chem‑Impex provides (R)-N‑Boc‑3‑Bromophenylalanine in both research‑grade and pharmaceutical‑grade purities, with a strong emphasis on quality control and traceability. The company’s logistics network ensures timely delivery to major CROs across North America.

Sustainability & Growth Initiatives:

• Implementation of digital supply‑chain monitoring to reduce lead times.
• Investment in renewable energy for manufacturing facilities.
• Partnerships with industry consortia to promote sustainable synthesis.

7. Apollo Scientific Ltd.

Headquarters: London, United Kingdom
Key Offering: High‑purity chiral intermediates for pharmaceutical R&D

Apollo Scientific’s (R)-N‑Boc‑3‑Bromophenylalanine is supplied in 99%+ purity, meeting stringent regulatory requirements for pre‑clinical development. The firm’s strong technical support assists clients in optimizing SPPS protocols.

Sustainability & Growth Initiatives:

• Adoption of solvent‑free reaction processes.
• Engagement with UK research councils on peptide therapeutics.
• Commitment to carbon neutrality by 2030.

8. Activate Scientific, Inc.

Headquarters: San Diego, California, USA
Key Offering: Specialty chemical synthesis for research and development

Activate Scientific offers (R)-N‑Boc‑3‑Bromophenylalanine in 99% purity, supporting high‑throughput screening and early‑stage medicinal chemistry. Its flexible production model accommodates rapid scale‑up for emerging projects.

Sustainability & Growth Initiatives:

• Development of recyclable Boc‑deprotection reagents.
• Partnerships with biotech startups to support novel peptide‑based modalities.
• Implementation of lean manufacturing principles.

9. Matrix Scientific

Headquarters: San Diego, California, USA
Key Offering: Custom synthesis of chiral amino acids for drug discovery

Matrix Scientific delivers (R)-N‑Boc‑3‑Bromophenylalanine in 99%+ purity, with a focus on rapid turnaround for academic and industrial clients. The company’s analytical capabilities ensure consistent enantiomeric excess across batches.

Sustainability & Growth Initiatives:

• Investment in green chemistry to reduce hazardous waste.
• Collaboration with CROs to provide on‑demand custom synthesis.
• Continuous improvement of reaction efficiency.

10. PharmaBlock Sciences Co., Ltd.

Headquarters: Shanghai, China
Key Offering: Large‑scale production of protected amino acids for the Asian market

PharmaBlock Sciences supplies (R)-N‑Boc‑3‑Bromophenylalanine in 99% purity, supporting domestic and international peptide manufacturing. The firm’s integrated supply chain delivers consistent quality to CROs and biopharma companies across Asia‑Pacific.

Sustainability & Growth Initiatives:

• Adoption of catalytic asymmetric synthesis to reduce raw‑material costs.
• Expansion of production capacity in China to meet growing demand for peptide therapeutics.
• Collaboration with Chinese research institutions on next‑generation peptide drugs.

Download FREE Sample Report

Get Full Report

Outlook (2026‑2034)

The forecast period is characterized by a steady expansion of peptide‑based drug pipelines, particularly in oncology and immunology. The compound’s role in SPPS and SAR studies is expected to sustain demand, with the market projected to reach USD 52.7 million by 2034. Key factors driving this trajectory include the adoption of advanced bioconjugation techniques, the rise of PROTACs and antibody‑drug conjugates, and the increasing emphasis on high‑purity, GMP‑grade intermediates.

Future Trends

1. PROTACs and ADC Linkers – The aryl halide functionality of (R)-N‑Boc‑3‑Bromophenylalanine facilitates late‑stage diversification, positioning it as a preferred building block for proteolysis‑targeting chimeras and antibody‑drug conjugates.

2. Green Chemistry Initiatives – Industry momentum toward biocatalytic and solvent‑free synthesis is expected to lower production costs by up to 30% and reduce environmental impact.

3. Supply‑Chain Resilience – Enhanced regional manufacturing hubs in Asia‑Pacific and the adoption of digital traceability tools will mitigate raw‑material volatility and improve lead‑time reliability.

4. Regulatory Alignment – Harmonized GMP and ISO standards across major markets will streamline approval processes for peptide‑based therapeutics, further expanding the customer base.